The FDA has approved ivosidenib (Tibsovo, Agios) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-1 (IDH1) mutation, as detected by the concurrently approved Abbott RealTime IDH1 diagnostic test.
Ivosidenib is the first oral IDH1 inhibitor option for patients with R/R AML with IDH1 mutation. Hagop M. Kantarjian, MD, the professor and chair of The University of Texas MD Anderson Cancer Center's Department of